Piper Sandler Upgrades Iovance Biotherapeutics to Overweight, Raises Price Target to $14
Piper Sandler analyst Joseph Catanzaro upgrades Iovance Biotherapeutics (NASDAQ:IOVA) from Neutral to Overweight and raises the price target from $11 to $14.